Recursion Pharma Files Proxy Solicitation Material
Ticker: RXRX · Form: DEFA14A · Filed: Sep 19, 2024 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | DEFA14A |
| Filed Date | Sep 19, 2024 |
| Risk Level | low |
| Pages | 7 |
| Reading Time | 9 min |
| Key Dollar Amounts | $1 billion, $200 million, $20 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, solicitation, corporate-governance
Related Tickers: RXRX
TL;DR
Recursion Pharma (RXRX) filed proxy materials, likely for shareholder votes or discussions.
AI Summary
Recursion Pharmaceuticals, Inc. filed a DEFA14A on September 19, 2024, related to soliciting materials under Rule 14a-12. The filing indicates no fee was required for this submission. The company, previously known as Recursion Pharmaceuticals, LLC, is incorporated in Delaware and headquartered in Salt Lake City, Utah.
Why It Matters
This filing signals that Recursion Pharmaceuticals is engaging in activities requiring shareholder communication and potentially seeking shareholder approval or input on corporate matters.
Risk Assessment
Risk Level: low — This is a routine filing for proxy solicitation materials and does not inherently indicate significant new risks.
Key Players & Entities
- Recursion Pharmaceuticals, Inc. (company) — Registrant
- Recursion Pharmaceuticals, LLC (company) — Former company name
- 41S RIO GRANDE STREET (location) — Company Business and Mail Address
- SALT LAKE CITY (location) — Company Business and Mail City
- UT (location) — Company Business and Mail State
- DE (location) — State of Incorporation
FAQ
What is the purpose of this DEFA14A filing?
This DEFA14A filing is for soliciting material under Rule 14a-12, indicating Recursion Pharmaceuticals is communicating with shareholders regarding corporate matters.
When was this filing submitted?
The filing was submitted on September 19, 2024.
What is Recursion Pharmaceuticals' primary business classification?
Recursion Pharmaceuticals is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.
What was the company's former name?
The company's former name was Recursion Pharmaceuticals, LLC, with a date of name change on March 5, 2014.
Was there a filing fee associated with this document?
No, the filing indicates that no fee was required for this submission.
Filing Stats: 2,249 words · 9 min read · ~7 pages · Grade level 16.9 · Accepted 2024-09-19 16:27:44
Key Financial Figures
- $1 billion — annual peak sales opportunities of over $1 billion each potential for approximately $200 m
- $200 million — illion each potential for approximately $200 million in milestone payments over the next 24
- $20 billion — ments over the next 24 months, and over $20 billion in revenue before royalties over the co
Filing Documents
- recursion-solicitationmate.htm (DEFA14A) — 34KB
- 0001601830-24-000158.txt ( ) — 35KB
Forward Looking Statements
Forward Looking Statements.